Introduction to KRT73-AS1, A Potential Drug Target (G100127967)
Introduction to KRT73-AS1, A Potential Drug Target
KRT73-AS1, also known as Keratin 73 antisense RNA 1, is a long non-coding RNA (lncRNA) that has recently gained attention as a potential drug target or biomarker in various diseases. This article aims to explore the characteristics and functions of KRT73-AS1, as well as its potential applications in diagnosis, prognosis, and therapy.
The Discovery of KRT73-AS1
KRT73-AS1 was initially identified as a lncRNA in a study exploring the role of non-coding RNAs in human diseases. Researchers discovered that KRT73-AS1 is transcribed from the opposite strand of the gene encoding Keratin 73, a member of the keratin family involved in the formation of hair fibers. The gene is located on chromosome 12q13.13. Since its discovery, KRT73-AS1 has been found to exhibit various important functions in multiple disorders.
Biomarker Potential of KRT73-AS1
One of the most intriguing aspects of KRT73-AS1 is its potential as a biomarker. Numerous studies have shown that dysregulation of KRT73-AS1 expression is associated with various diseases, including cancer, cardiovascular diseases, neurodegenerative disorders, and autoimmune conditions. For example, in several types of cancer, such as breast and lung cancer, increased expression of KRT73-AS1 has been observed in tumor tissues compared to healthy tissues. This aberrant expression pattern suggests that KRT73-AS1 could serve as a biomarker for early detection, monitoring treatment response, and predicting prognosis.
KRT73-AS1 in Cancer
In cancer research, KRT73-AS1 has emerged as a potential therapeutic target due to its involvement in key cancer-related pathways. Several studies have demonstrated that silencing KRT73-AS1 using specific inhibitors or siRNAs reduces cancer cell proliferation, induces apoptosis, and inhibits tumor growth in animal models.
Furthermore, KRT73-AS1 has been found to interact with important cancer-associated biomolecules, such as microRNAs, DNA methyltransferases, and histone-modifying enzymes. For example, KRT73-AS1 has been shown to sponge certain microRNAs, preventing them from repressing the expression of oncogenes. This interaction with microRNAs highlights KRT73-AS1's role in post-transcriptional regulation of gene expression and its potential as a therapeutic target.
Diagnostic and Prognostic Applications
The dysregulation of KRT73-AS1 expression observed in multiple diseases has paved the way for its potential use in diagnosis and prognosis. In prostate cancer, for instance, KRT73-AS1 has been found to correlate with clinical parameters such as tumor stage and Gleason score. Elevated expression of KRT73-AS1 in prostate tumor tissues can discriminate between aggressive and non-aggressive forms of the disease, aiding in personalized treatment decisions.
Similarly, in cardiovascular diseases, increased levels of KRT73-AS1 have been associated with the severity of coronary artery disease and heart failure. This finding suggests that KRT73-AS1 could serve as a valuable biomarker for risk stratification and monitoring disease progression.
The Role of KRT73-AS1 in Neurodegenerative Disorders
Emerging evidence suggests that KRT73-AS1 may also play a role in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. In Alzheimer's disease, increased expression of KRT73-AS1 has been detected in patient brain tissues, whereas decreased expression has been observed in Parkinson's disease. These findings indicate that KRT73-AS1 may participate in the pathological processes of neurodegeneration, opening up new avenues for therapeutic interventions.
KRT73-AS1, a lncRNA transcribed from the opposite strand of Keratin 73 gene, has demonstrated its potential as a drug target or biomarker in various diseases. Its dysregulated expression in cancer, cardiovascular diseases, neurodegenerative disorders, and autoimmune conditions suggests its roles in disease progression and prognosis. Furthermore, the ability of KRT73-AS1 to interact with key biomolecules and influence crucial cellular pathways makes it an attractive target for therapeutic intervention. Further research is warranted to fully elucidate the functional mechanisms of KRT73-AS1 and explore its clinical applications in precision medicine.
Protein Name: KRT73 Antisense RNA 1
More Common Targets
KRT78 | KRT8P33 | KRT8P36 | KRT8P37 | KRT8P39 | KRT8P44 | KRT8P46 | KRT8P48 | KRTAP16-1 | KRTAP20-4 | KRTAP21-3 | KRTAP22-2 | KRTAP25-1 | KRTAP29-1 | KRTAP4-7 | KRTAP4-9 | KRTAP9-6 | KRTAP9-7 | KTN1-AS1 | L1CAM-AS1 | L1TD1 | LAMTOR3P1 | LAMTOR5-AS1 | LARGE-AS1 | LARGE2 | LCA5 | LCDR | LCE4A | LCIIAR | LCT-AS1 | LCTL | LDHBP1 | LDHD | LEFTY2 | LEPROT | LEXM | LGALS8-AS1 | LGI4 | LHFPL2 | LHFPL6 | LHX4-AS1 | LIFR-AS1 | LIMS3-LOC440895 | LIMS4 | LIN28B-AS1 | LINC-ROR | LINC00029 | LINC00092 | LINC00102 | LINC00111 | LINC00112 | LINC00113 | LINC00158 | LINC00159 | LINC00160 | LINC00161 | LINC00173 | LINC00184 | LINC00189 | LINC00210 | LINC00240 | LINC00276 | LINC00278 | LINC00308 | LINC00311 | LINC00331 | LINC00333 | LINC00348 | LINC00351 | LINC00353 | LINC00358 | LINC00364 | LINC00398 | LINC00400 | LINC00402 | LINC00421 | LINC00423 | LINC00424 | LINC00426 | LINC00440 | LINC00446 | LINC00457 | LINC00462 | LINC00466 | LINC00484 | LINC00499 | LINC00501 | LINC00506 | LINC00507 | LINC00513 | LINC00534 | LINC00536 | LINC00538 | LINC00539 | LINC00540 | LINC00557 | LINC00559 | LINC00562 | LINC00563 | LINC00564